More importantly, we confirmed that compared to monotherapy and dual therapy, triple therapy consisting of CDKL1 overexpression, RT, and anti-PD-L1 antibody treatment has the most potent synergistic antitumor effect on lung cancer. Here, CD274 is linked to lung carcinoma.